As the wild and woolly days of the CBD boom fade away, those guys who make Epidiolex are looking awfully smart.
For years, GW Pharmaceuticals and its eventual parent, Jazz Pharmaceuticals, stood apart from the broader CBD craze that swept the world. While hundreds of companies rushed into wellness products, GW pursued a far slower and vastly more expensive strategy built around clinical trials, pharmaceutical regulation and aggressive lobbying.
The company’s cannabis-based treatments,
Epidyolex (spelled Epidiolex in the United States) and Sativex, which operate inside tightly controlled medical frameworks rather than consumer channels, have been on the market in Europe and the U.S. – legally – for years.
Recalibrating
The next phase of CBD in Europe is unlikely to resemble either the freewheeling wellness boom that defined the past decade or the fully mainstream consumer category many investors once envisioned. Instead, the market appears headed toward a future that is narrower, more controlled and significantly smaller – led by the pharma subsector.
That means Europe’s future CBD market will be defined less by consumer brands and more by healthcare distribution networks, pharma production standards and clinically oriented product development of expensive, niche products that address rare afflictions.
Non-pharma
As a result of the restrictive approach taken by EU and UK food safety authorities, non-pharma wellness CBD products are likely to survive mainly as ultra-low-dose formulations with limited commercial appeal. In many cases, those products may simply serve as legal fronts for higher-dose gray-market CBD sales that are expected to continue at the edges of what’s legal, online and through smaller specialty outlets.
THIS SERIES:
• PART 1: UK’s switch to EU food safety rules could push thousands of CBD products to dead end
• PART 2: Europe’s CBD bottleneck tightens as UK pathway stalls before EU regulatory handover
• PART 3: Europe’s CBD casualties mount as novel foods process radically reshapes the market
• PART 4: Pharma products poised to dominate Europe’s shrinking, tightly regulated CBD sector
Fragmented enforcement and uneven national oversight have long allowed CBD markets to operate in legally ambiguous territory across parts of Europe. That dynamic is unlikely to disappear entirely, particularly in countries where regulators lack either the resources or political appetite for aggressive enforcement.
But both the legal and the gray markets for wellness CBD are expected to remain small, European analysts say.
Medical = niche
With global sales of Epidyolex at roughly $1.1 billion, Jazz strides across a total regulated prescription CBD market that has been estimated at only a few billion dollars.
The company effectively established the modern template for such medicines in Europe and other regulated markets with Epidiolex and Sativex. (Epidyolex is a CBD-only drug, while Sativex is 50/50 CBD and THC).
It’s a niche market expected to grow as regulators in Europe and the UK put the squeeze on wellness CBD, and cannabis-based remedies advance into the medical mainstream.
Cosmetics questions
Cosmetics may ultimately represent another limited survival channel for CBD in Europe because topical products avoid many of the novel foods issues tied to ingestible products.
But even that category faces growing uncertainty because European regulators are also reviewing CBD through chemicals and cosmetics frameworks, where ongoing debates over whether CBD could harm fertility or fetal development could sharply limit or potentially eliminate its use in personal-care products.
Who’ll survive
As Europe’s CBD path has narrowed, many smaller brands have already disappeared, after years of delays, mounting compliance costs and uncertainty surrounding the UK and EU food-safety approval pathways.
CBD will remain part of the European landscape. But its role will be more limited, its pathways more tightly controlled and its economics more difficult than many once anticipated.
The companies best positioned to survive are those with deep financial resources and pharmaceutical-grade manufacturing systems, while established medical marijuana operators and drug companies can be expected to absorb CBD products into broader therapeutic portfolios.